Antigen-Specific T Cell Responses in Hepatocellular Carcinoma



Hepatocellular carcinoma (HCC) has a relatively high antigenicity and immunogenicity. In the past 10–15 years, several tumor-associated antigens (TAAs) and their T cell epitopes for HCC have been identified and studied to understand the immune responses in HCC patients. In addition, these TAAs and epitopes have been used for the development of immunotherapy of HCC. Recent clinical studies using peptide vaccines suggest that, while the efficacy against advanced cancers may be limited when used alone, they have a significant potential to prevent tumor recurrence, and to prolong survival and time-to-progression. Further development of immunotherapy in HCC will depend on the identification of highly immunogenic antigen-derived T cell epitopes, such as neoantigens, as well as a better understanding of the mechanisms underlying antitumor immunity.


Epitope Cytotoxic T lymphocyte Cancer Peptide vaccine Immunotherapy 


Conflict of Interest

The authors disclose no conflicts of interest.


  1. 1.
    Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546–58.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Yoong KF, McNab G, Hubscher SG, Adams DH. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol. 1998;160:3978–88.PubMedGoogle Scholar
  3. 3.
    Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology. 1998;27:407–14.CrossRefPubMedGoogle Scholar
  4. 4.
    van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Butterfield LH, Koh A, Meng W, Vollmer CM, Ribas A, Dissette V, et al. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res. 1999;59:3134–42.PubMedGoogle Scholar
  6. 6.
    Mizukoshi E, Nakamoto Y, Tsuji H, Yamashita T, Kaneko S. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. Int J Cancer. 2006;118:1194–204.CrossRefPubMedGoogle Scholar
  7. 7.
    Thimme R, Neagu M, Boettler T, Neumann-Haefelin C, Kersting N, Geissler M, et al. Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. Hepatology. 2008;48:1821–33.CrossRefPubMedGoogle Scholar
  8. 8.
    Mizukoshi E, Nakamoto Y, Marukawa Y, Arai K, Yamashita T, Tsuji H, et al. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology. 2006;43:1284–94.CrossRefPubMedGoogle Scholar
  9. 9.
    Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res. 2006;12:2689–97.CrossRefPubMedGoogle Scholar
  10. 10.
    Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gillet M, et al. Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol. 2005;174:1709–16.CrossRefPubMedGoogle Scholar
  11. 11.
    Zerbini A, Pilli M, Soliani P, Ziegler S, Pelosi G, Orlandini A, et al. Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma. J Hepatol. 2004;40:102–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Mizukoshi E, Honda M, Arai K, Yamashita T, Nakamoto Y, Kaneko S. Expression of multidrug resistance-associated protein 3 and cytotoxic T cell responses in patients with hepatocellular carcinoma. J Hepatol. 2008;49:946–54.CrossRefPubMedGoogle Scholar
  13. 13.
    Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Sakai A, Sakai Y, et al. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology. 2011;53:1206–16.CrossRefPubMedGoogle Scholar
  14. 14.
    Mizukoshi E, Fushimi K, Arai K, Yamashita T, Honda M, Kaneko S. Expression of chondroitin-glucuronate C5-epimerase and cellular immune responses in patients with hepatocellular carcinoma. Liver Int. 2012;32:1516–26.CrossRefPubMedGoogle Scholar
  15. 15.
    Mizukoshi E, Nakagawa H, Kitahara M, Yamashita T, Arai K, Sunagozaka H, et al. Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma. Cancer Lett. 2015;364:98–105.CrossRefPubMedGoogle Scholar
  16. 16.
    Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007;132:2328–39.CrossRefPubMedGoogle Scholar
  17. 17.
    Takata Y, Nakamoto Y, Nakada A, Terashima T, Arihara F, Kitahara M, et al. Frequency of CD45RO+ subset in CD4+CD25(high) regulatory T cells associated with progression of hepatocellular carcinoma. Cancer Lett. 2011;307:165–73.CrossRefPubMedGoogle Scholar
  18. 18.
    Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008;135:234–43.CrossRefPubMedGoogle Scholar
  19. 19.
    Arihara F, Mizukoshi E, Kitahara M, Takata Y, Arai K, Yamashita T, et al. Increase in CD14+HLA-DR −/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother. 2013;62:1421–30.CrossRefPubMedGoogle Scholar
  20. 20.
    Mizukoshi E, Yamashita T, Arai K, Sunagozaka H, Ueda T, Arihara F, et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology. 2013;57:1448–57.CrossRefPubMedGoogle Scholar
  21. 21.
    Zerbini A, Pilli M, Penna A, Pelosi G, Schianchi C, Molinari A, et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res. 2006;66:1139–46.CrossRefPubMedGoogle Scholar
  22. 22.
    Ayaru L, Pereira SP, Alisa A, Pathan AA, Williams R, Davidson B, et al. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol. 2007;178:1914–22.CrossRefPubMedGoogle Scholar
  23. 23.
    Iida N, Nakamoto Y, Baba T, Nakagawa H, Mizukoshi E, Naito M, et al. Antitumor effect after radiofrequency ablation of murine hepatoma is augmented by an active variant of CC Chemokine ligand 3/macrophage inflammatory protein-1alpha. Cancer Res. 2010;70:6556–65.CrossRefPubMedGoogle Scholar
  24. 24.
    Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Mukaida N, Matsushima K, et al. Enhancement of tumor-specific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma. Int J Cancer. 2010;126:2164–74.PubMedGoogle Scholar
  25. 25.
    Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res. 2006;12:2817–25.CrossRefPubMedGoogle Scholar
  26. 26.
    Nakamoto Y, Mizukoshi E, Kitahara M, Arihara F, Sakai Y, Kakinoki K, et al. Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization. Clin Exp Immunol. 2011;163:165–77.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Greten TF, Forner A, Korangy F, N’Kontchou G, Barget N, Ayuso C, et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer. 2010;10:209.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res. 2012;18:3686–96.CrossRefPubMedGoogle Scholar
  29. 29.
    Mizukoshi E. Association between high-avidity T-cell receptors, induced by alpha fetoprotein-derived peptides, and anti-tumor effects in patients with hepatocellular carcinoma. Gastroenterology. 2017;152:1395–406.CrossRefPubMedGoogle Scholar
  30. 30.
    Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126–9.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Kobayashi E, Mizukoshi E, Kishi H, Ozawa T, Hamana H, Nagai T, et al. A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days. Nat Med. 2013;19:1542–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP, et al. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res. 2004;10:4332–41.CrossRefPubMedGoogle Scholar
  33. 33.
    Pang PH, Chan KT, Tse LY, Chan RC, Cheung YK, Sin FW, et al. Induction of cytotoxic T cell response against HCA661 positive cancer cells through activation with novel HLA-A *0201 restricted epitopes. Cancer Lett. 2007;256:178–85.CrossRefPubMedGoogle Scholar
  34. 34.
    Xing Q, Pang XW, Peng JR, Yin YH, Li Y, Yu X, et al. Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587. Biochem Biophys Res Commun. 2008;372:331–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Kaji K, Mizukoshi E, Yamashita T, Arai K, Sunagozaka H, Fushimi K, et al. Cellular Immune Responses for Squamous Cell Carcinoma Antigen Recognized by T Cells 3 in Patients with Hepatocellular Carcinoma. PLoS One. 2017;12:e0170291.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Mizukoshi E, Nakagawa H, Kitahara M, Yamashita T, Arai K, Sunagozaka H, et al. Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma. Cancer Lett. 2015;369:242–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of Gastroenterology, Graduate School of MedicineKanazawa UniversityKanazawaJapan

Personalised recommendations